Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...
GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...
The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results